News
-
Kyowa Hakko Bio Partners with the Agency for Science, Technology and Research (ASTAR) to Study Human Milk Oligosaccharides (HMOs)
Kyowa Hakko Bio, a global leader in biotechnology and nutritional solutions, is thrilled to announce a groundbreaking collaboration with the Agency for ...
-
Kyowa Hakko Bio celebrates opening of expanded Cognizin citicoline manufacturing facility in Hofu, Japan
Kyowa Hakko Bio is thrilled to announce the grand opening of its expanded citicoline manufacturing facilities at the Kyowa Hakko Bio Yamaguchi Production Center...
-
Kyowa Hakko Bio Receives FDA No Question Letter For GRAS Notices On Human Milk Oligosaccharides
KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited, is pleased to announce that it has received a no question letter from the United States’ Food and Drug Administration (FDA)...
-
Kyowa Hakko Bio’s 6’-Sialyllactose Sodium Salt Receives Novel Food Approval in the EU
KYOWA HAKKO BIO CO., LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited, is pleased to announce that its 6’-Sialyllactose sodium salt (6’-SL), a Human Milk Oligosaccharide (HMO), has been approved as a Novel Food...
-
First in Europe - Innovative Vision Postbiotic EYEMUSE® to Combat Digital Eye Fatigue
Supersmart, a leading name in the field of dietary supplements and nutritional products, is proud to announce the launch of its groundbreaking product, Vision Postbiotic EYEMUSE®...
-
IMMUSE Postbiotic Wins Inaugural “Microbiome Modulation” Industry Award
IMMUSE postbiotic for immune health, has been honored as the inaugural recipient of the the Ingredient of the Year: Microbiome Modulation category...
-
Introducing Rebound: Your Ultimate Party Recovery Solution Featuring Setria® Glutathione
A new supplement concept to help you elevate your party recovery experience and unlock your body’s full potential in the days that follow.
-
Comple.med Launches the First Food Supplement in Europe Featuring IMMUSE®
Kyowa Hakko’s IMMUSE®, a clinically researched unique postbiotic, provides immune support in Lactoflor® Immuno 200...
-
Manufacturing strains of Kyowa Hakko Bio’s 3'-sialyllactose and 6’-sialyllactose, human milk oligosaccharides (HMOs), passed safety evaluation in China
KYOWA HAKKO BIO CO., LTD. (Kyowa Hakko Bio) is pleased to announce that its manufacturing strains used for producing 3'-sialyllactose (3’-SL) and 6’-sialyllactose (6’-SL) have passed the Chinese Ministry of Agriculture and Rural affairs’ (MARA) safety evaluation...
-
Completion Of Human Milk Oligosaccharides (HMOs) Production Facility
KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), completed a production facility for human milk oligosaccharides (HMOs) on November 18, 2022 at its Thai subsidiary, THAI KYOWA BIOTECHNOLOGIES CO., LTD.